LAC5 Antibody

Possible Nomenclature Misinterpretations

The acronym "LAC" frequently appears in immunological contexts but refers to distinct entities:

• Lupus Anticoagulant (LAC): A class of antiphospholipid antibodies associated with thrombotic disorders . These are autoantibodies, not therapeutic or diagnostic antibodies.

• LacZ Antibody: Targets β-galactosidase in research (e.g., clone 40-1a) , unrelated to "LAC5."

L2A5 Antibody

• Target: Sialyl-Tn (STn), a tumor-associated carbohydrate antigen .

• Key Findings:

  • Demonstrates specificity for STn-expressing cancers (e.g., breast, bladder) .

  • Superior tumor recognition in invasive/metastatic sites compared to other anti-STn antibodies .

  • Binds core STn and 2-6-linked sialyl core-1 glycans .

LAT1 Antibody (#5347)

• Target: L-type amino acid transporter 1 (LAT1/SLC7A5) .

• Research Applications:

  • Western blotting (1:1000 dilution)

  • Immunoprecipitation (1:100 dilution)

• Biological Role: Linked to tumor metabolism and progression .

Antiphospholipid Antibodies (Non-"LAC5" Context)

• LAC (Lupus Anticoagulant): Detected in COVID-19 patients with thrombotic complications .

  • Single LAC positivity observed in 51.6% of ICU patients .

  • Transient presence in acute infection phases .

Recommendations for Clarification

Given the absence of "LAC5 Antibody" in scientific records, the following steps are advised:

1. Verify the correct spelling or nomenclature (e.g., L2A5, LAT1, CEACAM5-targeted antibodies).

2. Consult updated antibody databases (e.g., Human Protein Atlas, Cell Signaling Technology).

3. Explore recent preprints or patents for emerging antibody candidates not yet indexed in major databases.